drugset / Trial / NCT02355938
Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
Phase 4
Terminated
12 enrolled
Baylor College of Medicine
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose of this study is to compare the clinical outcomes of cure and recurrence of Clostridium difficile infection in spinal cord injured patients who are treated with oral Fidaxomicin vs. oral Vancomycin. The secondary aim of this study is to compare the overall costs of treatment of Clostridium difficile infection in the two study groups.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fidaxomicin | Other / unclassified | 200 mg | Oral |
| Comparator | Vancomycin | Other / unclassified | 125 mg | Oral |